FDA Grants Approval For Topical Non-Steroidal Treatment

Ceragenix Pharmaceuticals, Inc., announced it has received 510K clearance from the FDA for its EpiCeram Skin Barrier Emulsion to improve dry skin conditions and relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis, and other dry skin conditions by maintaining a moist wound and skin environment. This topical, non-steroidal treatment that consists of a specific combination of lipids will be available by prescription only.